• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $VTGN

    Vistagen Therapeutics Inc.

    Subscribe to $VTGN
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.

    IPO Year:

    Exchange: NASDAQ

    Website: vistagen.com

    Peers

    $CLDX
    $RLMD

    Recent Analyst Ratings for Vistagen Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    12/7/2023$15.00Hold → Buy
    Jefferies
    8/7/2023$30.00Hold → Buy
    Maxim Group
    7/22/2022Outperform → Neutral
    Robert W. Baird
    7/22/2022Buy → Hold
    Jefferies
    7/22/2022Outperform → Mkt Perform
    William Blair
    See more ratings

    Vistagen Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

      New Data Build on Recent Epidemiology Findings Presented by the Company at the 2024 Neuroscience Education Institute Congress The Need for Improved Diagnosis and Treatment Options Underscored by Data Presented in Posters Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented new data on social anxiety disorder (SAD) at the 2025 Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada. The Company's poster presentations examined the age of onset of SAD in participants in the Company's fasedieno

      4/17/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Present at the 2025 Anxiety and Depression Association Conference

      Posters Highlight New Insights into Social Anxiety Disorder Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada from April 3 to 5, 2025. The Company's poster presentations will explore the age of onset of social anxiety disorder (SAD) from participants in fasedienol clinical trials, and new data on the characteristics of young adults with and without SAD. Poster Presentations: Date: Friday, April 4, 2025,

      3/19/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Participate in Stifel 2025 Virtual CNS Forum

      Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that management will participate in Stifel's 2025 Virtual CNS Forum. Vistagen's President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation on Tuesday, March 18, 2025, at 12 p.m. Eastern Time. A live webcast will be accessible through the "Events" page in the "Investors" section of the Company's website at www.Vistagen.com. A replay of the webcast will be archived and available following the event. About Vistagen Hea

      3/4/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

      Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present at the 45th Annual TD Cowen Healthcare Conference. Vistagen's President and Chief Executive Officer, Shawn Singh, will present a corporate overview on Monday, March 3, 2025, at 2:30 p.m. Eastern Time. A webcast will be accessible through the "Events" page in the "Investors" section of the Company's website at www.Vistagen.com. A replay of the webcast will be archived and available following the event. About Vistagen Headquartered in South San Francisco, CA, Vista

      2/20/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

      Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing with ongoing PALISADE-3, PALISADE-4 and Repeat Dose trials Vistagen highlights clinical-stage pipeline with five novel pherine product candidates with positive efficacy signals and potential to transform standards of care for multiple high prevalence indications Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 202

      2/13/25 4:30:00 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

      Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a corporate update. The conference call is being webcast live and a link can be found under "Events" in the Investors section of the Company's website. Participants may register for the live call link HERE to receive the dial-in numbers and uni

      2/6/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

      Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatment of neuropathic pain. The patent will not expire until at least 2034 and is part of Vistagen's global patent portfolio on manufacturing methods and therapeutic uses for AV-101 to treat various disorders involving the NMDA receptor. "This new patent advances our AV-101 portfolio and significantly strengthens our position for potential

      2/5/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

      PH284 nasal spray demonstrated improvements to subjective feelings of hunger in cancer patients PH284 is the fifth pherine product candidate in Vistagen's neuroscience pipeline with a positive efficacy signal Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced positive results from an exploratory Phase 2A study of PH284 in cancer cachexia. PH284 is an investigational pherine nasal spray differentiated from all current treatments for the loss of appetite associated with chronic disorders, such as cancer. In the study, PH284 demonstrated higher mean subjective feeling of hunger as compared to pla

      1/14/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

      All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety disorder are underway Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment of social anxiety disorder (SAD). The repeat dose study is a small exploratory U.S. Phase 2 multi-center, randomized, double-blind, placebo-controlled, three-arm clinical trial designed to assess the efficacy, safety, and tolerabi

      1/10/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Present at the Stifel 2024 Healthcare Conference

      Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place November 18 and 19, 2024 in New York City. Stifel 2024 Healthcare Conference Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Monday, November 18 at 3:35 p.m. Eastern Time. A webcast will be accessible through the "Events" page in the "Investors" section of the Company's website at www.Vistagen.com. Investors interested in arranging a one-on-one meeting during the conference should contact

      11/14/24 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Vistagen Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • VistaGen upgraded by Jefferies with a new price target

      Jefferies upgraded VistaGen from Hold to Buy and set a new price target of $15.00

      12/7/23 6:31:15 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VistaGen upgraded by Maxim Group with a new price target

      Maxim Group upgraded VistaGen from Hold to Buy and set a new price target of $30.00

      8/7/23 2:16:37 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VistaGen downgraded by Robert W. Baird

      Robert W. Baird downgraded VistaGen from Outperform to Neutral

      7/22/22 12:22:03 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VistaGen downgraded by Jefferies

      Jefferies downgraded VistaGen from Buy to Hold

      7/22/22 12:22:03 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VistaGen downgraded by William Blair

      William Blair downgraded VistaGen from Outperform to Mkt Perform

      7/22/22 9:09:26 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on VistaGen with a new price target

      Robert W. Baird initiated coverage of VistaGen with a rating of Outperform and set a new price target of $9.00

      5/20/21 7:02:34 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baird initiated coverage on VistaGen Therapeutics with a new price target

      Baird initiated coverage of VistaGen Therapeutics with a rating of Outperform and set a new price target of $9.00

      5/20/21 6:29:16 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies Financial Group initiated coverage on VistaGen Therapeutics with a new price target

      Jefferies Financial Group initiated coverage of VistaGen Therapeutics with a rating of Buy and set a new price target of $6.00

      2/25/21 10:46:14 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on VistaGen Therapeutics with a new price target

      Jefferies initiated coverage of VistaGen Therapeutics with a rating of Buy and set a new price target of $6.00

      2/18/21 6:42:02 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on VistaGen Therapeutics with a new price target

      Jefferies initiated coverage of VistaGen Therapeutics with a rating of Hold and set a new price target of $6.00

      2/18/21 6:42:02 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Vistagen Therapeutics Inc. SEC Filings

    See more
    • Vistagen Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

      3/6/25 4:51:39 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Vistagen Therapeutics Inc.

      SCHEDULE 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      2/14/25 4:40:23 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Vistagen Therapeutics Inc.

      SCHEDULE 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      2/14/25 4:28:38 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Vistagen Therapeutics Inc.

      10-Q - Vistagen Therapeutics, Inc. (0001411685) (Filer)

      2/13/25 5:25:15 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

      2/13/25 4:45:36 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

      2/5/25 5:04:59 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

      1/14/25 5:16:28 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

      1/13/25 5:28:45 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

      12/6/24 4:49:35 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

      11/7/24 4:38:10 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Vistagen Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Prince Joshua S. was granted 3,310 shares, increasing direct ownership by 124% to 5,981 units (SEC Form 4)

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      1/13/25 5:40:58 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn was granted 2,592 shares, increasing direct ownership by 72% to 6,184 units (SEC Form 4)

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      1/13/25 5:39:30 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cunningham Ann Michelle

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      9/10/24 5:00:10 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Curley Joanne

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      9/10/24 5:00:12 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gin Jerry B

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      9/10/24 5:00:15 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Saxe Jon S

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      9/10/24 5:00:15 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Fitzpatrick Margaret M

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      9/10/24 5:00:07 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Rotunno Mary L.

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      9/10/24 5:00:08 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Prince Joshua S. was granted 2,671 shares (SEC Form 4)

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      7/2/24 6:10:04 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn was granted 3,592 shares (SEC Form 4)

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      7/2/24 6:08:51 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Vistagen Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

      Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join toget

      10/9/24 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Appoints Cindy Anderson as Chief Financial Officer

      Anderson succeeds Jerrold Dotson who is retiring after a distinguished decade-long career with Vistagen Vistagen (NASDAQ:VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson as Chief Financial Officer (CFO), effective August 21, 2023. Ms. Anderson will succeed Jerrold Dotson, whose planned retirement was announced in July of this year. "We are delighted to welcome Ms. Anderson, an experienced and highly accomplished finance professional, to our team," said Shawn Singh, Chief Executive Officer of V

      8/22/23 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022

      Annual Meeting to resume October 28, 2022 to vote on Proposal No. 5 to provide Vistagen's Board of Directors the option to implement a future reverse stock split of the Company's issued and outstanding common stock, if necessary to maintain the Company's listing on the Nasdaq Capital Market, and Proposal No. 6 to allow for an amendment to the Company's Bylaws Vistagen Therapeutics, Inc. (NASDAQ:VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced results of voting and the partial adjournment of the Company's 2022 Annua

      10/19/22 4:30:00 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VistaGen Appoints Reid Adler as Chief Legal Officer

      VistaGen Therapeutics, Inc. (NASDAQ:VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced the appointment of Reid Adler as its Chief Legal Officer. Adler will oversee VistaGen's legal affairs and provide strategic guidance to its Executive Team and Board of Directors. "We are excited to welcome Reid to VistaGen's Executive Team," said Shawn Singh, Chief Executive Officer. "He is a visionary, trusted advisor and proven leader who brings deep legal experience across numerous domains as well a passion for helping

      5/2/22 8:00:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system ("CNS") disorders, today announced the appointment of Maggie FitzPatrick to its Board of Directors ("Board"), replacing Dr. Brian J. Underdown who recently retired from the Board. "Maggie is a highly-regarded public affairs strategist with extensive experience developing and executing multiple high impact customer-focused marketing communications initiatives for some of the world's la

      7/22/21 8:00:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system ("CNS") disorders, today announced the appointment of Mary L. Rotunno, J.D. to its Board of Directors ("Board"). "Mary brings to our team more than 30 years of leadership experience, which began with serving patients as a registered nurse and transitioned to serving clients in health care law, both allowing her to pursue her steadfast commitment to helping others and advancing the futur

      7/7/21 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer

      SOUTH SAN FRANCISCO, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system ("CNS") disorders, today announced the appointment of Ann Cunningham as its Chief Commercial Officer. Ms. Cunningham has a proven pharmaceutical commercial track record of more than 25 years delivering sales, marketing, and global life cycle product management expertise in roles across several healthcare markets, including neuropsychiatry and other CNS markets that VistaGen is pursuing. Sh

      5/4/21 8:00:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system ("CNS") disorders, today announced the appointment of Joanne Curley, Ph.D. to its Board of Directors ("Board"). Following the appointment of Dr. Curley, VistaGen's Board will be comprised of seven directors. "Joanne brings more than 25 years of pharmaceutical industry experience across numerous key operational and therapeutic areas," said Shawn Singh, Chief Executive Officer of VistaGe

      4/27/21 8:00:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Vistagen Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

      Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing with ongoing PALISADE-3, PALISADE-4 and Repeat Dose trials Vistagen highlights clinical-stage pipeline with five novel pherine product candidates with positive efficacy signals and potential to transform standards of care for multiple high prevalence indications Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 202

      2/13/25 4:30:00 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

      Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a corporate update. The conference call is being webcast live and a link can be found under "Events" in the Investors section of the Company's website. Participants may register for the live call link HERE to receive the dial-in numbers and uni

      2/6/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

      Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3 and PALISADE-4 Phase 3 trials initiated and underway Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update. "We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet another significant milestone in our fasedienol U.S. registration-directed Phase 3 Program for the acute treatment of social anxiety disorder," said Shawn Singh, Ch

      11/7/24 4:20:00 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

      Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide a corporate update. Event: Vistagen Fiscal Year 2025 Second Quarter Corporate Update Conference Call Date: Thursday, November 7, 2024 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-800-717-1738 TOLL/International Dial-in: 1-646-307-1865 Conference ID: 1196845 Webcast: https://viavid.webcasts.com/s

      11/1/24 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

      PALISADE Phase 3 Program for the acute treatment of Social Anxiety Disorder progressing on track Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 first quarter ended June 30, 2024, and provided a corporate update. "Building on the success of our PALISADE-2 Phase 3 trial of fasedienol, our rapid-onset, non-systemic pherine nasal spray for the acute treatment of social anxiety disorder, our top priority remains driving forward our

      8/13/24 4:21:00 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

      Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Tuesday, August 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 first quarter ended June 30, 2024 and provide a corporate update. Event: Vistagen Fiscal Year 2025 First Quarter Corporate Update Conference Call Date: Tuesday, August 13, 2024 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-877-

      8/6/24 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

      Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 ended March 31, 2024 and provide a corporate update. Event: Vistagen Fiscal Year 2024 Corporate Update Conference Call Date: Tuesday, June 11, 2024 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-877-407-9716 TOLL/International Dial-in: 1-201-493-6779 Conference ID: 13746589 Webcast:

      6/7/24 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

      Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on track PALISADE-3 trial initiation anticipated in 1H 2024; PALISADE-4 trial initiation anticipated in 2H 2024 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update. "Momentum from clinical and corporate milestones achieved through the end of last quarter have significantly advanced our efforts to develop and commercialize fasedienol as a potent

      2/13/24 4:20:00 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024

      Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, February 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 third quarter ended December 31, 2023 and provide a corporate update. Event: Vistagen Fiscal Year 2024 Third Quarter Corporate Update Conference Call Date: Tuesday, February 13, 2024 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-877-407-9716 TOLL/International Dial-in: 1-201-493-6779 Conference ID: 137

      2/6/24 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023

      Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, November 9, 2023, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to provide a corporate update and report results for its fiscal year 2024 second quarter ended September 30, 2023. Event: Vistagen Fiscal Year 2024 Second Quarter Corporate Update Conference Call Date: Thursday, November 9, 2023 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-800-245-3047 TOLL/International

      11/6/23 8:00:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Vistagen Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

      SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      11/14/24 5:05:41 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

      SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      11/14/24 4:19:46 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by VistaGen Therapeutics Inc. (Amendment)

      SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      2/14/24 6:18:34 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by VistaGen Therapeutics Inc.

      SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      2/14/24 4:51:40 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by VistaGen Therapeutics Inc. (Amendment)

      SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      2/14/24 4:39:17 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by VistaGen Therapeutics Inc. (Amendment)

      SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      2/14/24 8:56:03 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by VistaGen Therapeutics Inc.

      SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      2/13/24 5:17:36 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by VistaGen Therapeutics Inc.

      SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      10/16/23 4:37:27 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by VistaGen Therapeutics Inc.

      SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      10/16/23 4:34:29 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by VistaGen Therapeutics Inc.

      SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      10/16/23 4:01:10 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care